腫瘍治療薬の中国市場:化学療法、標的療法、免疫療法、ホルモン療法...市場調査レポートについてご紹介

【英文タイトル】China Oncology Drugs Market by Drug Class Type (Chemotherapy, Targeted Therapy, Immunotherapy, and Hormonal Therapy) and Indication (Blood Cancer, Breast Cancer, Gastrointestinal Cancer, Prostate Cancer, Lung Cancer, Skin Cancer, Ovarian Cancer, Cervical Cancer, Kidney Cancer, and Other Cancers): Opportunity Analysis and Industry Forecast, 2019-2026

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

Chapter 1: Introduction

1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments

1.3.1. List of Key Players Profiled In The Report

1.4. Research Methodology

1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools And Models

Chapter 2: Executive Summary

2.1. Key Findings of The Study
2.2. Cxo Perspective

Chapter 3: Market Overview

3.1. Market Definition And Scope
3.2. Key Findings

3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies, 2018

3.3. Porter’S Five Forces Analysis
3.4. Market Dynamics

3.4.1. Drivers

3.4.1.1. Industrial Collaboration
3.4.1.2. In House Manufacturing
3.4.1.3. Increase In Incidences of Cancers In The Chinese Population

3.4.2. Restraint

3.4.2.1. Preference of Generics And Biosimilars

3.4.3. Opportunity

3.4.3.1. Increase In Number of Pipeline Drugs

3.4.4. Impact Analyses

Chapter 4: China Oncology Drugs Market, By Drug Class Type

4.1. Overview

4.1.1. Market Size And Forecast

4.2. Chemotherapy

4.2.1. Key Market Trends, Growth Factors, And Opportunities
4.2.2. Market Size And Forecast

4.3. Targeted Therapy

4.3.1. Key Market Trends, Growth Factors, And Opportunities
4.3.2. Market Size And Forecast

4.4. Immunotherapy (Biologic Therapy)

4.4.1. Key Market Trends, Growth Factors, And Opportunities
4.4.2. Market Size And Forecast

4.5. Hormonal Therapy

4.5.1. Key Market Trends, Growth Factors, And Opportunities
4.5.2. Market Size And Forecast

Chapter 5: China Oncology Drugs Market, By Indication

5.1. Overview

5.1.1. Cancer Incidences In China, 2018
5.1.2. Market Size And Forecast

5.2. Blood Cancer

5.2.1. Market Size And Forecast

5.3. Breast Cancer

5.3.1. Market Size And Forecast

5.4. Gastrointestinal And Urinary Cancer

5.4.1. Market Size And Forecast
5.4.2. Gb/Cholangiocarcinoma

5.4.2.1. Market Size And Forecast

5.4.3. Bladder Cancer

5.4.3.1. Market Size And Forecast

5.4.4. Pancreatic Cancer

5.4.4.1. Market Size And Forecast

5.5. Prostate Cancer

5.5.1. Market Size And Forecast

5.6. Lung Cancer

5.6.1. Market Size And Forecast
5.6.2. Small Cell Lung Cancer (Sclc)

5.6.2.1. Market Size And Forecast

5.7. Skin Cancer

5.7.1. Market Size And Forecast

5.8. Ovarian Cancer

5.8.1. Market Size And Forecast

5.9. Cervical Cancer

5.9.1. Market Size And Forecast

5.10. Kidney Cancer

5.10.1. Market Size And Forecast,

5.11. Other Cancers

5.11.1. Market Size And Forecast

Chapter 6: Company Profiles

6.1. Abbvie Inc.

6.1.1. Company Overview
6.1.2. Company Snapshot
6.1.3. Operating Business Segments
6.1.4. Product Portfolio
6.1.5. Business Performance

6.2. Astellas Pharma Inc.

6.2.1. Company Overview
6.2.2. Company Snapshot
6.2.3. Operating Business Segments
6.2.4. Product Portfolio
6.2.5. Business Performance

6.3. Astrazeneca Plc

6.3.1. Company Overview
6.3.2. Company Snapshot
6.3.3. Operating Business Segments
6.3.4. Product Portfolio
6.3.5. Business Performance

6.4. Bristol-Myers Squibb Company

6.4.1. Company Overview
6.4.2. Company Snapshot
6.4.3. Operating Business Segments
6.4.4. Product Portfolio
6.4.5. Business Performance
6.4.6. Key Strategic Moves And Developments

6.5. Celgene Corporation

6.5.1. Company Overview
6.5.2. Company Snapshot
6.5.3. Operating Business Segments
6.5.4. Product Portfolio
6.5.5. Business Performance
6.5.6. Key Strategic Moves And Developments

6.6. F. Hoffmann-La Roche Ltd.

6.6.1. Company Overview
6.6.2. Company Snapshot
6.6.3. Operating Business Segments
6.6.4. Product Portfolio
6.6.5. Business Performance
6.6.6. Key Strategic Moves And Developments

6.7. Johnson & Johnson

6.7.1. Company Overview
6.7.2. Company Snapshot
6.7.3. Operating Business Segments
6.7.4. Product Portfolio
6.7.5. Business Performance
6.7.6. Key Strategic Moves And Developments

6.8. Shanghai Junshi Biosciences Co., Ltd.

6.8.1. Company Overview
6.8.2. Company Snapshot
6.8.3. Operating Business Segments
6.8.4. Product Portfolio
6.8.5. Business Performance
6.8.6. Key Strategic Moves And Developments

6.9. Beigene

6.9.1. Company Overview
6.9.2. Company Snapshot
6.9.3. Operating Business Segments
6.9.4. Product Portfolio
6.9.5. Business Performance
6.9.6. Key Strategic Moves And Developments

6.10. Jiangsu Hengrui Medicine Co., Ltd.

6.10.1. Company Overview
6.10.2. Company Snapshot
6.10.3. Operating Business Segments
6.10.4. Product Portfolio
6.10.5. Key Strategic Moves And Developments


【レポート販売概要】

■ タイトル:腫瘍治療薬の中国市場:化学療法、標的療法、免疫療法、ホルモン療法
■ 英文:China Oncology Drugs Market by Drug Class Type (Chemotherapy, Targeted Therapy, Immunotherapy, and Hormonal Therapy) and Indication (Blood Cancer, Breast Cancer, Gastrointestinal Cancer, Prostate Cancer, Lung Cancer, Skin Cancer, Ovarian Cancer, Cervical Cancer, Kidney Cancer, and Other Cancers): Opportunity Analysis and Industry Forecast, 2019-2026
■ 発行日:2019年8月
■ 調査会社:Allied Market Research
■ 商品コード:AMR9NV120
■ 調査対象地域:中国
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。